Skip to content

Ketamine: all studies

Page 390 of 449: studies 3,891 to 3,900 of 4,486, newest first. Back to the ketamine overview

Research

Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms.

Current Topics in Behavioral Neurosciences July 31, 2024 Friederike Holze, Matthias E. Liechti, Felix Müller 4 citations

Psychedelics are a group of substances within the heterogeneous class of hallucinogenic drugs. Via binding to the serotonin (5-HT) 2A receptor, psychedelics exert profound alterations in various mental domains, including sensation, cognition, emotions, and self-perception. Psychedelics comprise phenethylamines (e.g., mescaline), tryptamines (e.g., psilocybin), and ergolines (e.g., LSD). These...

DOI: 10.1007/7854_2024_510 (opens in new tab) Full text (opens in new tab) Classification Psychedelics hallucinogens Entheogens Psychoactive drugs +5

Distinct alterations in probabilistic reversal learning across at-risk mental state, first episode psychosis and persistent schizophrenia.

Scientific Reports July 30, 2024 J. D. Griffin, K. M. J. Diederen, J. Haarsma et al. 5 citations

We used a probabilistic reversal learning task to examine prediction error-driven belief updating in three clinical groups with psychosis or psychosis-like symptoms. Study 1 compared people with at-risk mental state and first episode psychosis (FEP) to matched controls. Study 2 compared people diagnosed with treatment-resistant schizophrenia (TRS) to matched controls. The design replicated our...

DOI: 10.1038/s41598-024-68004-7 (opens in new tab) Full text (opens in new tab) Psychosis Schizophrenia Decision-making Cognitive behavior +1

Exploring the Impact of Recreational Drugs on Suicidal Behavior: A Narrative Review

Psychoactives July 3, 2024 Rosa María Moret, Sergio Sanz‐gómez, Santiago Gascón et al. 4 citations

Substance use/abuse and suicide are two closely related phenomena, mostly due to neurobiological, psychological, and social impairments. In the present narrative review, the relationship between suicidal behavior (SB) and the use and abuse of common recreational drugs, such as alcohol, cannabis, cocaine, methamphetamine, heroin, nicotine, ketamine, psilocybin, MDMA, and LSD, has been explored....

Chronic Neuropathic Pain and Comorbid Depression Syndrome: From Neural Circuit Mechanisms to Treatment.

ACS Chemical Neuroscience July 3, 2024 Yue Zhang, Hui Ma, Yafan Bai et al. 25 citations

Chronic neuropathic pain and comorbid depression syndrome (CDS) is a major worldwide health problem that affects the quality of life of patients and imposes a tremendous socioeconomic burden. More than half of patients with chronic neuropathic pain also suffer from moderate or severe depression. Due to the complex pathogenesis of CDS, there are no effective therapeutic drugs available. The lack...

DOI: 10.1021/acschemneuro.4c00125 (opens in new tab) Full text (opens in new tab) Chronic neuropathic pain Neural circuit Chronic-pain Mental-health +2

What is needed for the roll-out of psychedelic treatments?

Current Opinion in Psychiatry July 1, 2024 Stephen N. Xenakis, Scott Shannon 5 citations

The pace of psychedelic treatments continues to increase. Regulation and coherent clinical guidance have not been established. A philosophical divide limits effective resolution of a practice delivery quandary: is this primarily a pharmacological or psychotherapeutic intervention? Lykos (formerly MAPS) has submitted its new drug application (NDA) request to the FDA for...

Innovative and Emerging Treatments for Anorexia Nervosa

FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2024 Sasha Gorrell, Amanda E. Downey 3 citations

Unlike psychopharmacologic interventions for other psychiatric conditions, few medications have emerged as helpful in improving eating disorder cognitions and evidence-based psychotherapies fail many patients. Novel treatments are urgently needed to address anorexia nervosa (AN), which is increasingly prevalent and difficult to treat. This article provides an overview of preliminary...

IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?

Journal of Pakistan Psychiatric Society June 30, 2024 Nauman Ashraf 1 citation

Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religious ceremonies to facilitate spiritual experiences. Lysergic acid diethylamide (LSD) was used clinically from the 1950s until its ban in 1967. Recently, there has been a resurgence of interest in psychedelics for treating mental health disorders such...

Efficacy and Safety of Pharmacological Treatment in Patients with Complex Regional Pain Syndrome: A Systematic Review and Meta-Analysis.

Pharmaceuticals June 20, 2024 He Zhu, Bei Wen, Jijun Xu et al. 15 citations

Complex regional pain syndrome (CRPS) is a disabling condition that usually affects the extremities after trauma or surgery. At present, there is no FDA-approved pharmacological treatment for patients with CRPS. We performed this systematic review and meta-analysis to evaluate the efficacy and safety of pharmacological therapies and determine the best strategy for CRPS. We searched the...

DOI: 10.3390/ph17060811 (opens in new tab) Full text (opens in new tab) Pain relief Pharmacological treatment Chronic pain Pain management +6

Licit use of illicit drugs for treating depression: the pill and the process.

Journal of Clinical Investigation June 17, 2024 Alejandro Torrado Pacheco, Bita Moghaddam 3 citations

Psilocybin, MDMA, and ketamine have emerged as potentially effective treatments for rapid amelioration of the symptoms of mood and related psychiatric disorders. All clinical data collected so far with regard to psilocybin or MDMA, which have reported positive outcomes for treating depression, anxiety, posttraumatic stress disorder, and drug or alcohol use disorders, have involved...

DOI: 10.1172/jci180217 (opens in new tab) Full text (opens in new tab) Psychedelic therapy Depression treatment Therapeutic environment Integrative medicine +1

Nicolas Garel: Combining psychoactive molecules and psychotherapy for patients suffering from mood and substance use disorders: a new therapeutic paradigm

Psychedelics June 14, 2024 N. Garel

Dr Nicolas Garel is an Assistant Professor in the Department of Psychiatry and Addictology at the University of Montreal and a junior investigator at the Research Center of the Centre Hospitalier de l'Université de Montréal. Dr Garel did his psychiatry residency at McGill University before completing the Clinician-Investigator Program and a Master's degree at McGill University, studying the...